Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Hutchmed China Ltd ADR (HCM)

Hutchmed China Ltd ADR (HCM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,840,634
  • Shares Outstanding, K 174,272
  • Annual Sales, $ 838,000 K
  • Annual Income, $ 100,780 K
  • 60-Month Beta 0.83
  • Price/Sales 3.44
  • Price/Cash Flow 27.64
  • Price/Book 4.01
Trade HCM with:

Options Overview Details

View History
  • Implied Volatility 79.74% ( +45.34%)
  • Historical Volatility 44.23%
  • IV Percentile 61%
  • IV Rank 52.94%
  • IV High 126.14% on 01/29/24
  • IV Low 27.53% on 07/12/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 5
  • Put/Call OI Ratio 0.76
  • Today's Open Interest 227
  • Open Int (30-Day) 214

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.82 +3.16%
on 09/10/24
18.64 -12.45%
on 08/19/24
-2.15 (-11.64%)
since 08/16/24
3-Month
15.82 +3.16%
on 09/10/24
20.55 -20.58%
on 08/12/24
-1.49 (-8.37%)
since 06/18/24
52-Week
11.93 +36.75%
on 02/05/24
21.92 -25.55%
on 05/10/24
+0.34 (+2.13%)
since 09/18/23

Most Recent Stories

More News
Inmagene and HUTCHMED Announce First Participant in Global Phase I Trial of IMG-004

SAN DIEGO and SHANGHAI, China and HONG KONG, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Inmagene Biopharmaceuticals ("Inmagene") and HUTCHMED (China) Limited...

HCM : 16.32 (+0.12%)
HCM.LN : 245.000 (-1.21%)
HUTCHMED and AstraZeneca Announce that TAGRISSO® Plus Savolitinib Demonstrated 49% Objective Response Rate in Lung Cancer Patients with High Levels of MET Overexpression and/or Amplification in SAVANNAH Phase II Trial

— MET is the most common biomarker in patients with EGFR-mutated lung cancer who develop resistance to targeted therapy — — Global SAFFRON Phase...

HCM : 16.32 (+0.12%)
HCM.LN : 245.000 (-1.21%)
HUTCHMED Announces that Fruquintinib Global Phase III FRESCO-2 Study Has Met Its Primary Endpoint in Metastatic Colorectal Cancer

— Trial met primary endpoint of overall survival and all secondary endpoints — — Overall safety consistent with fruquintinib known profile — — Plans for...

HCM : 16.32 (+0.12%)
HCM.LN : 245.000 (-1.21%)
HUTCHMED Reports 2022 Interim Results and Provides Business Updates

Oncology/Immunology revenues up 113% to $91.1 million, due to ELUNATE®, SULANDA® and ORPATHYS® growth First presentation of SAVANNAH data...

HCM : 16.32 (+0.12%)
HCM.LN : 245.000 (-1.21%)
HUTCHMED Initiates a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 01, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today...

HCM : 16.32 (+0.12%)
HCM.LN : 245.000 (-1.21%)
HUTCHMED Initiates Phase I Trial of Anti-CD47 Monoclonal Antibody HMPL-A83 in Patients with Advanced Malignant Neoplasms in China

HMPL-A83 is the thirteenth innovative oncology drug candidate discovered in-house by HUTCHMED and its second large molecule drug candidate to enter...

HCM : 16.32 (+0.12%)
HCM.LN : 245.000 (-1.21%)
HUTCHMED Highlights First Presentation of Results of the SAVANNAH Global Phase II Trial of Savolitinib plus TAGRISSO® at the 2022 WCLC Annual Meeting

— 49% ORR amongst SAVANNAH patients with higher MET levels —...

HCM : 16.32 (+0.12%)
HCM.LN : 245.000 (-1.21%)
Inmagene and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-007

SAN DIEGO and SHANGHAI and HONG KONG and SYDNEY, Australia, July 06, 2022 (GLOBE NEWSWIRE) -- Inmagene Biopharmaceuticals ("Inmagene") and HUTCHMED...

HCM : 16.32 (+0.12%)
HCM.LN : 245.000 (-1.21%)
HUTCHMED to Announce 2022 Half-Year Financial Results

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., June 27, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13)...

HCM : 16.32 (+0.12%)
HCM.LN : 245.000 (-1.21%)
HUTCHMED Announces TAZVERIK® Approved to be Used in Hainan Pilot Zone in China

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13)...

HCM : 16.32 (+0.12%)
HCM.LN : 245.000 (-1.21%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

HUTCHMED Limited is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. HUTCHMED Limited, formerly known as HUTCHMED...

See More

Key Turning Points

3rd Resistance Point 16.93
2nd Resistance Point 16.79
1st Resistance Point 16.54
Last Price 16.32
1st Support Level 16.15
2nd Support Level 16.01
3rd Support Level 15.76

See More

52-Week High 21.92
Fibonacci 61.8% 18.11
Fibonacci 50% 16.93
Last Price 16.32
Fibonacci 38.2% 15.75
52-Week Low 11.93

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar